- Open to women under the age of 40 who have been newly diagnosed with cancer (exclusive of breast cancer)
- Participants must have not congenital syndromes associate with infertility or any planned radiation to the pelvis
Detailed eligibility will be reviewed when contacting the study team.
This study is being done to see if receiving the medication triptorelin during chemotherapy reduces the chances of ovarian damage compared to having the chemotherapy without receiving triptorelin in women under the age of 40 with cancer.
Protecting the ovaries during chemotherapy is not part of the usual approach to cancer treatment. Some patients may have eggs or ovarian tissue removed and frozen before the beginning of treatment.
Participants will either receive a dose of the study drug triptorelin before starting their prescribed chemotherapy, or they will have the prescribed chemotherapy without triptorelin.
Triptolerin is approved by the U.S. Food and Drug Administration (FDA).
A pregnancy test is required before beginning the study. Blood samples will be taken four times: before cancer treatment begins; at the end of cancer treatment;1 year after the end of cancer treatment; 2 years after the end of cancer treatment. Participants will also be asked to fill out surveys throughout the study.
After finishing cancer treatment, the doctor and study team will continue to follow participants during routine clinic visits once per year for 2 years.